Senticell Raises Nearly $7M for RBC Liquid Biopsy

Senticell has closed an oversubscribed Seed financing approaching $7M to advance a liquid-biopsy platform built around red blood cells. The company says the capital will support prospective clinical studies and development of technology licensed exclusively from the University of Pennsylvania.

The round included TheVentureCity, Capital Factory, Scalpel Ventures, Evoce Capital, and high-net-worth investors. Senticell was co-founded by CEO Neha Shah and Chief Scientific Advisor Nilam Mangalmurti, whose Penn research established the scientific foundation for the platform.

The financing matters because most liquid-biopsy workflows analyze plasma after red blood cells, or RBCs, have been removed. Senticell is testing whether those discarded cells bind and preserve nucleic acids that could expose disease signals plasma-only analysis misses. Roughly 300 patients are enrolled or planned across 2 prospective cancer studies.

What Senticell Announced

Senticell announced an oversubscribed Seed round approaching $7M on September 1, 2026. The company did not disclose a valuation, individual investor allocations, or a single lead investor, so the precise description is a Seed financing approaching $7M rather than a completed $7M round.

TheVentureCity, Capital Factory, Scalpel Ventures, and Evoce Capital participated alongside unnamed high-net-worth individuals. Senticell says the money will advance clinical validation of its RBC-based liquid-biopsy platform, expand its team, and support the work required to translate university research into a repeatable diagnostic process.

Senticell is built around technology exclusively licensed from Penn. Neha Shah serves as co-founder and CEO. Nilam Mangalmurti is co-founder and Chief Scientific Advisor. The operating team also includes COO Mallik Srivatsan and Chief Business Officer Kartik Shah.

Why Red Blood Cells Are the Product Question

Liquid biopsy generally searches blood for biological material associated with disease. Plasma is a natural target because it contains cell-free DNA and other circulating molecules that can be measured without an invasive tissue biopsy. The practical workflow, however, begins by separating plasma from the cellular components of blood.

Senticell is challenging that first assumption rather than polishing the final assay. Research from Mangalmurti's Penn laboratory indicates that RBCs can bind nucleic acids through proteins on their surface. If disease-related nucleic acids attach to RBCs, removing the cells before analysis may also remove a portion of the signal.

That does not automatically make every RBC a diagnostic hard drive. The useful question is narrower: can an assay recover reproducible, disease-relevant signals from RBCs that improve on what clinicians can measure through plasma and tissue comparisons? Senticell has financing now. The studies have to supply the answer.

The platform grew from Penn research on red-cell immunobiology, including work in sepsis and pneumonia. Peer-reviewed research has described how red blood cells can bind circulating cell-free nucleic acids and how those interactions change during illness. Senticell is directing that biological mechanism toward cancer detection and characterization.

The Clinical Evidence Plan

Senticell says 2 prospective studies will cover about 300 patients. A Penn study involving roughly 200 people with lung and pancreatic cancers is expected to complete in Q1 2027. A second study involving about 100 patients with head-and-neck and cervical cancers is running across Penn and Penn-Botswana, with results expected in Q4 2026.

Both programs are designed to compare signals captured from RBCs with plasma-based liquid biopsy and tissue analysis. That comparison is the center of the investment case. A compelling mechanism creates permission to run the experiment, but diagnostic value depends on sensitivity, specificity, repeatability, and the clinical context in which the result could change a decision.

The prospective design also helps separate retrospective pattern-finding from real-world performance. Researchers can decide what they are measuring before outcomes are known, use defined cohorts, and compare the RBC signal against established samples and methods. The enrollment numbers are still early for a broad diagnostic claim, but they are large enough to start testing whether the signal survives outside a discovery dataset.

Why Investors Are Funding a Different Sample Layer

Liquid-biopsy companies have spent years competing on better sequencing, better chemistry, better classifiers, and better ways to extract faint signals from plasma. Senticell is opening another lane by reconsidering which fraction of the blood deserves to be measured.

That distinction matters economically as well as scientifically. If RBC-bound nucleic acids provide complementary information, the platform could expand the usable signal without requiring a new sample collection ritual. Blood is already routinely drawn. The operational burden would move into processing, assay design, and interpretation rather than into a more invasive procedure.

The risk lives in that same promise. A signal can be biologically interesting without becoming clinically useful. RBC-bound material may vary by disease, stage, collection protocol, time to processing, or other conditions. Any commercial test would also need analytical validation, clinical validation, a defined intended use, and an appropriate regulatory path. The Seed round finances the transition from a plausible mechanism toward that stack of evidence.

TheVentureCity and Capital Factory have backed companies at early stages where technical proof and company formation happen together. Scalpel Ventures and Evoce Capital add more capital around the same bet. None of those names substitutes for data, but their participation shows the thesis was fundable before the clinical comparison is finished.

What the Senticell Round Signals

Senticell's nearly $7M round reflects a broader shift in diagnostics: progress may come from finding a neglected biological compartment, not only from making an existing measurement more sensitive. The blood sample has not changed. The map of where useful information might live has.

That framing is attractive because it creates a proprietary starting point. Senticell has an exclusive Penn license and a scientific lineage tied to Mangalmurti's research. The defensibility question will extend beyond patents into sample handling, assay performance, datasets, clinical relationships, and the ability to show that RBC-derived information changes a result that matters.

The next milestones are unusually legible for an early-stage platform. The smaller study is expected to report in Q4 2026, and the larger study is expected to complete in Q1 2027. Those cohorts should indicate whether the RBC layer adds stable signal across multiple cancer types and whether the platform deserves a larger validation program.

Nearly $7M has funded a precise question hiding inside a familiar tube of blood. If the comparison works, red blood cells stop looking like the fraction removed before liquid biopsy begins. They become part of the biopsy.